tbuckley/cabot-search huggingface dataset:
AB1151 Bone profile in moroccan children with juvenile idiopathic arthritis
Authors: D. El Badri, S. Rostom, I. Bouaddi, A. Hassani, B. Chkirate, B. Amine, N. Hajjaj-Hassouni
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disorder of childhood. Beside other complication, it can lead to bone metabolism disturbance and osteoporosis. This bone loss is associated with several factors including low vitamin D. The aim of this study was to determine the prevalence of low bone mineral density (BMD) and hypovitaminosis D in Moroccan patients with juvenile idiopathic arthritis <h3>Methods</h3> In this cross-sectional study, Thirty three children with JIA, according to the classification criteria of International League of Associations for Rheumatology (ILAR), were included. The evaluation concerned a Patients underwent anthropometric assessment and clinical evaluation. Serum 25-hydroxyvitamin D2 et D3, other bone markers and BMD were measured. Bone mineral density (in g/cm<sup>2</sup>) was expressed in Z-scores, the number of standard deviation above or below the mean value of an age- and sex-matched reference population. In children, low BMD was defined as a Z-score less than -2 and osteoporosis was defined as a Z-score less than -2 with a fracture history. Hypovitaminosis D was defined as serum 25-hydroxyvitamin D &lt;30 ng/mL. <h3>Results</h3> The median of age of the patients was 11 years [6-14]. Bone mineral density in lumbar spine showed a statistically significant correlation with weight (β=0.613, IC at 95% [0.005-0.013], p=0.001) and age (β=0.5, IC at 95% [0.01-0.044], p=0.003) and the BMD in total body showed a statistically significant correlation only with weight (β=0.33, IC at 95% [0-0.008], p=0.05). There was a positive correlation between 1,25 dihydroxyvitamin D and disease activity (r = -0.52, p=0.03). No relationship was found between vitamin d and BMD and others bone markers. <h3>Conclusions</h3> Our study suggests that osteopenia was a frequent complication of JIA and it is associated to a low age and low body mass index (BMI). Its also shows that Vitamin D deficiency is highly prevalent among pediatric patients with JIA and it was associated with important activity of the disease. <h3>Disclosure of Interest</h3> None Declared
Authors' reply to National Joint Registry
Authors: D. J. W. McMinn, J. Daniel, R. B. C. Treacy, R. D. Riley
Journal: BMJ (2012)

The National Joint Registry (NJR) was aware that the data supplied would be used by clinical teams associated with Smith & Nephew (including first author McMinn).1 2 The data were originally requested because the NJR’s editorial chairman invited McMinn “to criticise registry data . . . to support the value of resurfacing” at the British and Irish Orthopaedic Congress 2011. McMinn therefore asked Smith …
Abstract 606: Inhibitory effects of piceatannol on tumor angiogenesis and lung metastasis in the 4T1 mammary cancer model
Authors: Hyerim Song, Eun Ji Kim, Jung Han Yoon Park
Journal: Cancer Research (2012)

Abstract Piceatannol (trans-3,4,3′,5′-tetrahydroxystilbene) is a polyphenol found in Rheum undulatum, grapes, red wine, and berries and has been shown to exert anticarcinogenic effects. In the present study, we determined whether oral administration of piceatannol inhibits solid tumor growth, angiogenesis, and lung metastasis of mammary cancer cells. 4T1 cells (5 x 104 cells) were injected into the mammary fat pad of syngeneic, 6-week old, female BALB/c mice. One day after, the mice were subjected to gavage for 30 days with piceatannol (0, 10, or 20 mg/kg body weight/day). Oral piceatannol treatment induced a significant reduction in the growth of solid tumors. Immunohistochemical staining of tumor tissues revealed that the expression of Ki67 (prototypic cell cycle related nuclear antigen), cyclin D1, cyclin A, cyclin-dependent kinase (CDK)4, CDK2, hypoxia-inducible factor 1, vascular endothelial growth factor, CD31 (platelet endothelial cell adhesion molecule-1) and LYVE-1 (lymphatic vessel endothelial receptor 1) was significantly decreased in the mice received 20 mg/kg piceatannol as compared to mice received vehicle. Piceatannol significantly increased the numbers of TUNEL-positive, apoptotic cells in tumor tissues, which was accompanied by increased Bax and cleaved caspase-3 expression and reduced Bcl-2 expression. Additionally, piceatannol feeding reduced the number and volume of pulmonary tumor nodules, which was accompanied by reduced expression of matrix metalloproteinase-9 in lung tissues. Piceatannol induced a significant reduction in the blood levels of chemokine ligand (CXCL) 16, CXCL13 (BCA-1), interleukin-16, macrophage colony-stimulating factor, monocyte chemoattractant protein-1, triggering receptor expressed on myeloid cells-1, stromal cell-derived factor-1, and plasminogen activator inhibitor-1 compared to the vehicle-fed mice. The present results indicate that piceatannol has an ability to inhibit breast cancer development and metastasis and this effect is attributable to its ability to inhibit tumor angiogenesis, lymphangiogenesis and reduce the blood levels of a broad variety of cytokines and chemokines. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 606. doi:1538-7445.AM2012-606
An unusual case of colorectal human papillomavirus infection
Authors: C. Cardoso, F. Augusto, I. Cremers
Journal: Endoscopy (2012)

A 48-year-old healthy woman presented to our hospital with a 2-week history of watery diarrhea. Sigmoidoscopy showed a white plaque at the rectosigmoid junction, with spared rectal mucosa ([Fig. 1]). Histologic examination revealed squamous stratified epithelium with features of human papillomavirus (HPV) infection, without dysplasia. The polymerase chain reaction analysis confirmed the presence of HPV, genotype 61.
A Whole Blood Colorimeter for Continuous Registration of Evans Blue Dye Concentration
Authors: W. FALHOLT, E. KAISER
Journal: Circulation Research (1955)

A whole blood colorimeter was developed which permits cardiac output determination after the injection of 5 to 15 mg. of Evans blue dye, resulting in maximal excursions of 5 to 11 cm. The apparatus permits sampling of blood through a cardiac catheter and its sensitivity is independent of the oxygen saturation and hematocrit of the blood sampled.
PTU-018 Can Chromoendoscopy help in Coeliac Disease as Part of a Duodenal Biopsy Strategy?
Authors: A J Johnston, M Kurien, K E Evans, A Averginos, D S Sanders
Journal: Gut (2013)

<h3>Introduction</h3> Chromoendoscopy is increasingly being used to detect, localise and characterise mucosal abnormalities, however its role in coeliac disease remains to be established. Endoscopic markers of coeliac disease (reduction of folds, scalloping, mosaic pattern, visible blood vessels and nodularity of the duodenal folds) are often difficult to recognise, therefore many centres take routine duodenal biopsies or have a low threshold for biopsy, ensuring high detection rates. This study evaluates if dye spray can improve identification of endoscopic markers of coeliac disease, potentially leading to a biopsy avoidance strategy. <h3>Methods</h3> Patients undergoing clinically indicated oesophogastroduodenoscopy (OGD) were prospectively recruited from a single endoscopy list between January 2011 and November 2012. Patients were divided into two groups: patients with no previous history of coeliac disease (Group 1, n = 201) and patients with established coeliac disease (Group 2, n = 24). Eight experienced endoscopists undertook all procedures, with endoscopic findings reported both before and after the use of indigo carmine dye spray. Endoscopic findings were compared using a McNemar test, with p values &lt; 0.05 considered significant. In addition, endoscopic findings were compared to histological findings to determine sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) for differing endoscopic techniques. <h3>Results</h3> Of the 225 patients recruited, 97 (43%) had positive serology (either endomysial or tissue transglutaminase antibodies). In Group 1, 61(30%) were newly diagnosed coeliac patients with endoscopic markers identified in 44% (27/61). Dye spray use within the duodenum identified a further 5 patients (32/61, 52%), however this improvement in diagnostic yield was not statistically significant (P = 0.63). Sensitivity, specificity, positive and negative predictive values for standard endoscopy to detect coeliac disease were 44%, 99%, 93%, 80% respectively compared to 52%, 99%, 94%, 83% for chromoendoscopy. In Group 2, 12 patients had persisting Marsh 3 changes at biopsy, however endoscopic markers were identified in only 5 (21%) with dye only increasing yield by a further one patient (6/24, 25%). <h3>Conclusion</h3> Dye spray is easy to use and inexpensive (&lt;£1/endoscopy), however in our study derived no additional benefit to conventional endoscopy for diagnosing patients with coeliac disease. Given the low sensitivity of endoscopic markers, we advocate duodenal biopsies in all patients where there is a high clinical suspicion of coeliac disease, irrespective of the endoscopic mucosal findings. <h3>Disclosure of Interest</h3> None Declared
AB1217 Methotrexate and low incidence of uveitis in children suffering from persistend or extended oligoarthriitis
Authors: W. Emminger, S. Fodor, G. Pichler, A. Ulbrich, M. Funk, T. Barisani
Journal: Annals of the Rheumatic Diseases (2012)

<h3>Background</h3> The incidence of uveitis in children suffering from persistent or extended oligoarthritis has been shown to be about 17 to 32%. Uveitis and its local corticosteroid (CS) therapy are associated with a high rate of acute and chronic ocular complications and are responsible for a significant morbidity in children and in adulthood. <h3>Methods</h3> We retrospectively analysed all consecutively treated children of a single pediatric rheumatology outpatient clinic, who were receiving weekly methotrexate (MTX) for therapy of oligoarthritis during the time period from January 2002 to November 2011. In order to study a population which is at a high risk to develop uveitis, inclusion criteria were as follows: age below seven years at the first episode of oligoarthritis and an observation time period of at least 6 months. Exclusion criteria were: other types of juvenile idiopathic arthritis (JIA) and a diagnosis of uveitis before the onset of oligoarthritis. The children underwent slit lamp examinations at regular intervals, most of them were examined at the department of ophthalmology of the Medical University of Vienna. <h3>Results</h3> 30 children, 24 girls and 6 boys, fulfilled the inclusion criteria, 29 of them were positive for antinuclear antibodies. The age at the start of arthritis was median 2 7/12 years (1 3/12- 6 6/12).The time duration from the onset of arthritis to the start of MTX therapy was median 4 months (2-30 months). The median duration of MTX therapy was 30 months (8-77). The median observation time after start of oligoarthritis was 47,5 months (24-106). During continuing MTX therapy, only one of 30 children had a diagnosis of uveitis and this was diagnosed just 3 months after the start of MTX therapy. In one other child, a first episode of an anterior uveitis was diagnosed 3 months after MTX had been stopped after tapering it. <h3>Conclusions</h3> In this retrospective analysis the observation time after the diagnosis of oligoarthritis was long with median 47,5 months (24-106). MTX therapy was associated with a very low incidence of uveitis in children suffering from persistent or extended oligoarthritis. Uveitis is associated with a high rate of acute and late complications due to the disease and due to topical CS therapy. The significant morbidity due to late ocular complications may be reduced in those children, who are receiving MTX for therapy of persistent or extended oligorarthritis. <h3>Disclosure of Interest</h3> None Declared
Protection of chemo-radiation therapy induced oral mucositis (OM) in pre-clinical and clinical studies
Authors: A. Rehemtulla, W. Grove, P. Sunkara, M. Naidu, B. D. Ross
Journal: Journal of Clinical Oncology (2006)

5567 Background: D-methionine, was shown to selectively protect normal but not tumor cells from loss of mitochondrial integrity and viability in response to ionizing radiation. OM is a debilitating complication of radiotherapy (RT) and chemotherapy (CT). MRx-1024, a orally bio-available formulation of this agent was evaluated as a treatment for the protection of OM. Methods: A mouse model of radiation-induced lip erythema was used to evaluate the efficacy of MRx-1024. Pharmacokinetic profile of MRX-1024 in healthy human volunteers as well as evaluation of oral MRX-1024 was accomplished in patients (pts) with head and neck cancer receiving RT or RT+CT. Pts received 1.8–2.0 Gy of RT daily for 5 days each week, to a total of 60 Gy. Selected pts also received cisplatin, 50mg/m 2 weekly. MRX-1024 suspension was given 1 hour before and again after each RT fraction. Pts were evaluated weekly using 4 accepted scales for assessing OM. Results: A significant protection of radiation-induced lip erythema was achieved in pre-clinical studies without compromising tumor control. Plasma concentrations of MRx-1024 achieved in normal volunteers after oral administration were similar to those required for efficacy in pre-clinical studies. No major adverse events were attributed to MRx-1024. The incidence of OM from 21 evaluable pts was compared with historical controls from the same institution. MRX-1024 was found to be a safe, easily administered and well-tolerated agent that completely ameliorated the incidence of Grade 4 (21% in historical controls) and reduced the incidence of Grade 3 by 80% over historical controls. In addition, preliminary analysis indicated that MRX-1024 did not compromise antitumor activity. Conclusions: These pre-clinical and clinical studies provide exciting proof of principle evidence for the use of MRx-1024 in the treatment of OM. Follow-up clinical studies are underway to further validate these results. [Table: see text]
P224 Lymph Node Assessment In Surgical Resection Of Non-small Cell Lung Cancer (nsclc): Are We Hitting The Target?
Authors: A. McKay, H. Ewan, G. Beattie, A. Kirk, M. Asif
Journal: Thorax (2014)

<h3>Introduction</h3> Guidelines from the British Thoracic Society (BTS) and the National Institute for Health and Care Excellence (NICE) recommend that nodal assessment be performed in all patients who have anatomical lung resection for NSCLC. Nodal status is one of the major determinants of outcome and most multidisciplinary teams now record adequacy of nodal assessment. N1 nodes are removed with the specimen perforce; therefore, a better indicator of surgical performance is the number of N2 nodal stations sampled. This paper describes a continual audit cycle of lymph node sampling performance data in relation to N2 nodes. <h3>Methods</h3> A retrospective analysis of patients who underwent anatomical lung resection for NSCLC in the calendar years 2009, 2010, 2012 and 2013 was undertaken. Lymph node sampling data was taken from pathology reports. The number of different stations sampled, rather than number of individual lymph nodes, was counted. Basic patient demographics were also collected. After each audit cycle individual results were tracked and presented at open local, regional and national forums. <h3>Results</h3> A total of 937 patients were audited after anatomic lung resection for NSCLC during the study periods. Pathology of NSCLC resections were as follows: 52% adenocarcinoma, 33.9% squamous cell carcinoma, 7.3% large cell carcinoma, 6.1% other. The data is summarised in the table below: <h3>Conclusion</h3> Audit over the past 3 years shown steady improvement in lymph node assessment performance. Continuous auditing and presentation of individual surgeon data at local, regional and national forums has contributed to the increasing compliance to the guideline targets There remains scope for further improvement and consultant engagement. Re-auditing will be essential to further improve compliance with guidelines.
SAT0291 Reduced joint counts misclassify PSA patients with oligoarthritis and miss significant active disease
Authors: L.C. Coates, O. Fitzgerald, D.D. Gladman, N. McHugh, P. Mease, V. Strand, P.S. Helliwell
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Despite recommendations to use full joint counts to assess patients with PsA, reduced joint counts designed for RA are often used for reporting outcomes in PsA registry studies and are used in clinical practice to assess patients with PsA. Analysis of RCTs suggested that 28 joint counts were responsive in PsA but this analysis was based on polyarticular patients enrolled into drug trials. <h3>Objectives</h3> The aim of this analysis was to investigate full and reduced joint counts in patients with oligoarticular PsA. <h3>Methods</h3> The study was an analysis of baseline visits for patients in the GRACE study, an international observational cohort recruited to develop new outcome measure in PsA. Oligoarthritis was defined as less than 5 tender and swollen joints. At baseline, full 76/78 tender and swollen joint counts were assessed. Reduced joint counts used for RA including the 28 and 44 joint count were analysed for comparison. In addition, new proposed shortened joint counts for PsA were tested to investigate their possible future use: PsA-44 (elbows, wrists, MCPs, PIPs, DIPs, knees and MTPs) and PsA-56 (as before plus ankles and PIP toes). ROC analysis was used to see how well different joint counts predicted treatment change for high disease activity. The proportion of patients with active disease missed by reduced joint counts was also analysed. <h3>Results</h3> In the cohort of 503 patients, 270 were classified as oligoarthritis. ROC analysis revealed that tender joint counts did not predict treatment change for high disease activity even when using a full 78 joint count (AUC 0.54, p=0.32). A 76 SJC did predict treatment change (AUC 0.61, p=0.008) as did a 66 SJC and the SJC PsA44 and PsA56 (p&lt;0.04). Neither of the RA reduced joint counts showed a significant relationship with treatment change. Of the 270 patients, 164 patients did not have any tender joints identified on a 28 joint count. However, of these 164, 38 did have 1 or more tender joints that had been missed (23%), leaving 126 patients with no tender joints. The PsA-44 and PsA-56 missed tender joints in 18 and 7 patients respectively. When considering swollen joints, 256 patients did not have any swollen joints identified on a 28 joint count but 48 of these (19%) did have swollen joints elsewhere. The PsA-44 and PsA-56 missed swollen joints in 26 and 7 patients respectively. <h3>Conclusions</h3> Patients with oligoarticular PsA cannot be assessed using joint counts borrowed from RA. Ideally full joint counts should be performed to assess PsA patients with the 66/68 joint count being the preferred measure due to difficulties distinguishing between the PIPs and DIPs of the toes. Reduced joint counts designed specifically for PsA do show correlation with treatment change but can still underestimate disease activity. <h3>Disclosure of Interest</h3> None Declared
Abstract 1022: Carfilzomib demonstrates broad antitumor activity in preclinical lung cancer models.
Authors: Amanda F. Baker, Barbara Sands, Lilliana Carbajal, Janet Anderl, Elena T. Chan, Christopher J. Kirk, Linda L. Garland
Journal: Cancer Research (2013)

Abstract Carfilzomib (CFZ), is an irreversible inhibitor of the chymotrypsin-like activity of the proteasome that was recently FDA approved for treatment of refractory and relapsed multiple myeloma. Early Phase 1B studies of CFZ showed signs of clinical activity in a number of solid tumors, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). We investigated the anti-tumor activity of CFZ monotherapy and in combination with cisplatin in NSCLC and SCLC cell lines and xenograft models. CFZ showed marked anti-proliferative activity in A549, H1993, H520, H460, H1299 NSCLC cell lines, with IC50 values after 96 hours of treatment ranging from 1.0 nM to 27 nM. CFZ + cisplatin resulted in antagonistic anti-proliferative activity in the NSCLC A549, H1993, and H520 cells, independent of sequence of drug administration. In vivo, CFZ monotherapy resulted in tumor growth inhibition in an A549 NSCLC murine xenograft model. In contrast, the SCLC cell lines SHP77 and H69 were more resistant to the anti-proliferative effects of CFZ, with IC50 values at 96 hours of 0.917 μM and &amp;gt;30 μM, respectively. In vitro, in the SHP-77 SCLC cell line CFZ + Cisplatin showed synergistic activity. In vivo, in a SHP-77 SCLC SCID murine xenograft model CFZ monotherapy resulted in an 8-day tumor growth delay to reach 1500 mm3. No additive or synergistic anti-tumor efficacy was observed for CFZ + cisplatin in this model. Western blot analysis from SHP-77 cell lines grown in vitro and treated with CFZ showed an increase in cleaved PARP and p53, supporting activation of apoptosis. We will report on inhibition of the chymotrypsin-like proteasome activity in CFZ-treated lung cancer cell lines. Together, these pre-clinical studies support further preclinical and clinical investigations of CFZ in NSCLC and SCLC, including novel CFZ + anti-cancer drug combinations. Citation Format: Amanda F. Baker, Barbara Sands, Lilliana Carbajal, Janet Anderl, Elena T. Chan, Christopher J. Kirk, Linda L. Garland. Carfilzomib demonstrates broad antitumor activity in preclinical lung cancer models. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1022. doi:10.1158/1538-7445.AM2013-1022
The Pulmonary Artery in COPD — Does Size Matter?
Authors: Matthew B. Stanbrook
Journal: New England Journal of Medicine (2012)

Wells et al.1 report in the Journal the association between pulmonary artery enlargement, defined as the diameter of the pulmonary artery on computed tomography (CT) greater than the corresponding diameter of the aorta (PA:A ratio >1), and an increased risk of future exacerbations of chronic obstructive pulmonary disease (COPD). An increased PA:A ratio had a greater association with future COPD exacerbations than any other variable evaluated, including a history of exacerbations. Although these findings are noteworthy, their implications for clinical practice are not yet clear.Many randomized trials showing that existing therapies are effective in reducing exacerbations of COPD have . . .
558 HCV KINETICS DURING AND AFTER THE ANHEPATIC PHASE: IS THE LIVER THE PRIMARY SITE FOR HCV CLEARANCE?
Authors: T.L. Chung, G. Crespo, L. Mensa, S. Pérez-del-Pulgar, M. Navasa, S.J. Cotler, X. Forns, H. Dahari
Journal: Journal of Hepatology (2013)
Brain PET in the Diagnosis of Alzheimer’s Disease
Authors: Charles Marcus, Esther Mena, Rathan M. Subramaniam
Journal: Clinical Nuclear Medicine (2014)

The aim of this article was to review the current role of brain PET in the diagnosis of Alzheimer dementia. The characteristic patterns of glucose metabolism on brain FDG-PET can help in differentiating Alzheimer's disease from other causes of dementia such as frontotemporal dementia and dementia of Lewy body. Amyloid brain PET may exclude significant amyloid deposition and thus Alzheimer's disease in appropriate clinical setting. FDG-PET and amyloid PET imaging are valuable in the assessment of patients with Alzheimer's disease.